{"entity":{"id":"nct06650566","kind":"trial","name":"Study of LM-299 in Subjects Advanced Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of LM-299 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","summary":"Study of LM-299 in Subjects Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06650566 by LaNova Medicines Limited, with 108 participants planned, started 2024-10-09 and due to reach its primary completion in 2026-12. Interventions recorded: LM-299.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06650566","url":"https://clinicaltrials.gov/study/NCT06650566"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06650566","phase":"1/2","setting":"A Phase I/II, Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LM-299 Injection as Monotherapy or in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","sponsor":"LaNova Medicines Limited","enrolled":108,"outcomes":[]},"route":"/trials/nct06650566/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"}]}}